364 related articles for article (PubMed ID: 19377213)
1. Serum soluble interleukin-2 receptor alpha in systemic lupus erythematosus.
El-Shafey EM; El-Nagar GF; El-Bendary AS; Sabry AA; Selim AG
Iran J Kidney Dis; 2008 Apr; 2(2):80-5. PubMed ID: 19377213
[TBL] [Abstract][Full Text] [Related]
2. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
3. Soluble interleukin-2 receptor levels in lupus nephritis.
Laut J; Senitzer D; Petrucci R; Sablay LB; Barland P; Glicklich D
Clin Nephrol; 1992 Oct; 38(4):179-84. PubMed ID: 1424303
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.
Heshmat NM; El-Kerdany TH
Pediatr Allergy Immunol; 2007 Jun; 18(4):346-53. PubMed ID: 17346298
[TBL] [Abstract][Full Text] [Related]
5. [Neopterin and a soluble interleukin-2 receptor in patients with systemic lupus erythematodes].
Horák P; Hermanová Z; Ordeltová M; Faltýnek L; Kusá L; Budíková M; Vavrdová V; Opíchalová D; Ciferská H; Scudla V
Vnitr Lek; 2004 Jun; 50(6):422-7. PubMed ID: 15346634
[TBL] [Abstract][Full Text] [Related]
6. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease.
Brugos B; Kiss E; Dul C; Gubisch W; Szegedi G; Sipka S; Zeher M
Hum Immunol; 2010 Sep; 71(9):874-7. PubMed ID: 20538031
[TBL] [Abstract][Full Text] [Related]
7. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.
Svenungsson E; Gunnarsson I; Fei GZ; Lundberg IE; Klareskog L; Frostegård J
Arthritis Rheum; 2003 Sep; 48(9):2533-40. PubMed ID: 13130473
[TBL] [Abstract][Full Text] [Related]
8. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
Mak A; Cheung BM; Mok CC; Leung R; Lau CS
Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
[TBL] [Abstract][Full Text] [Related]
9. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus.
Sabry AA; Elbasyouni SR; Kalil AM; Abdel-Rahim M; Mohsen T; Sleem A
Nephrology (Carlton); 2006 Aug; 11(4):329-35. PubMed ID: 16889573
[TBL] [Abstract][Full Text] [Related]
10. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M
Anticancer Res; 2001; 21(4B):3053-9. PubMed ID: 11712810
[TBL] [Abstract][Full Text] [Related]
11. [The importance of determination of interleukin-10 in the blood of patients with systemic lupus erythematosus].
Scudla V; Horák P; Faltýnek L; Pospísil Z; Budíková M; Hermanová Z
Cas Lek Cesk; 1998 Jan; 137(2):44-7. PubMed ID: 9511265
[TBL] [Abstract][Full Text] [Related]
12. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
13. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus.
Kümpers P; David S; Haubitz M; Hellpap J; Horn R; Bröcker V; Schiffer M; Haller H; Witte T
Ann Rheum Dis; 2009 Oct; 68(10):1638-43. PubMed ID: 18930996
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of cellular FLICE-inhibitory protein in peripheral blood B lymphocytes in patients with systemic lupus erythematosus is associated with clinical characteristics.
Tao J; Dong J; Li Y; Liu YQ; Yang J; Wu Y; Li L; Shen GX; Tan ZJ; Tu YT
J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):433-7. PubMed ID: 19335730
[TBL] [Abstract][Full Text] [Related]
15. Estimation of monocyte-chemoattractantprotein-1 (Mcp-1) level in patients with lupus nephritis.
Alzawawy A; Zohary M; Ablordiny M; Eldalie M
Int J Rheum Dis; 2009 Dec; 12(4):311-8. PubMed ID: 20374368
[TBL] [Abstract][Full Text] [Related]
16. Serum thrombomodulin in systemic lupus erythematosus and juvenile idiopathic arthritis.
el-Gamal YM; Heshmat NM; el-Kerdany TH; Fawzy AF
Pediatr Allergy Immunol; 2004 Jun; 15(3):270-7. PubMed ID: 15209962
[TBL] [Abstract][Full Text] [Related]
17. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.
Marto N; Bertolaccini ML; Calabuig E; Hughes GR; Khamashta MA
Ann Rheum Dis; 2005 Mar; 64(3):444-8. PubMed ID: 15286009
[TBL] [Abstract][Full Text] [Related]
18. The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus.
Kwan BC; Tam LS; Lai KB; Lai FM; Li EK; Wang G; Chow KM; Li PK; Szeto CC
Rheumatology (Oxford); 2009 Dec; 48(12):1491-7. PubMed ID: 19773408
[TBL] [Abstract][Full Text] [Related]
19. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
Wais T; Fierz W; Stoll T; Villiger PM
J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
[TBL] [Abstract][Full Text] [Related]
20. The relationship between soluble interleukin 2 receptor levels and antidouble stranded DNA antibody levels in patients with systemic lupus erythematosus.
Ward MM; Dooley MA; Christenson VD; Pisetsky DS
J Rheumatol; 1991 Feb; 18(2):235-40. PubMed ID: 2023217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
